for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bausch Health Companies Inc

BHC.TO

Latest Trade

40.74CAD

Change

0.54(+1.34%)

Volume

520,319

Today's Range

40.16

 - 

40.89

52 Week Range

16.30

 - 

41.38

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
40.20
Open
40.32
Volume
520,319
3M AVG Volume
14.13
Today's High
40.89
Today's Low
40.16
52 Week High
41.38
52 Week Low
16.30
Shares Out (MIL)
355.62
Market Cap (MIL)
14,295.92
Forward P/E
6.95
Dividend (Yield %)
--

Next Event

Bausch Health Companies Inc at JPMorgan Global High Yield & Leveraged Finance Conference (Virtual)

Latest Developments

More

Bausch Health Companies Inc Announces Fourth-Quarter And Full-Year 2020 Results, Provides 2021 Guidance

Glenview Capital Management Releases Letter To Joe Papa, CEO

BAUSCH HEALTH RESPONDS TO SCHEDULE 13D FILING FROM ICAHN CAPITAL LP

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bausch Health Companies Inc

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Industry

Biotechnology & Drugs

Contact Info

2150 Saint-Elzear Blvd W

LAVAL, QC

H7L 4A8

Canada

+1.514.7446792

https://www.bauschhealth.com/

Executive Leadership

Joseph C. Papa

Chairman of the Board, Chief Executive Officer

Paul S. Herendeen

Chief Financial Officer, Executive Vice President

Thomas J. Appio

President & Co-Head Bausch + Lomb/International

Joseph F. Gordon

President & Co-Head Bausch + Lomb/International

Christina M. Ackermann

Executive Vice President, General Counsel

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

8.4K

2019

8.6K

2020

8.0K

2021(E)

8.7K
EPS (USD)

2018

3.970

2019

4.360

2020

3.980

2021(E)

4.576
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.41
Price To Book (MRQ)
21.12
Price To Cash Flow (TTM)
8.93
Total Debt To Equity (MRQ)
4,471.96
LT Debt To Equity (MRQ)
4,471.96
Return on Investment (TTM)
-2.08
Return on Equity (TTM)
-1.72

Latest News

Latest News

UPDATE 2-Under eye of Icahn, Bausch Health gives activist investor two board seats

Bausch Health Companies Inc on Wednesday agreed to add two directors from Icahn Group to its board, weeks after activist investor Carl Icahn disclosed a nearly 8% stake in the Canadian drugmaker.

Bausch Health to add two directors from Icahn Group to board

Bausch Health Companies Inc said on Wednesday it would add two directors from Carl Icahn and affiliated entities to its board, weeks after the billionaire investor disclosed a stake in the company. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

UPDATE 1-Bausch Health investor Glenview calls for eye care spinoff in 2021

Glenview Capital Management, a shareholder in Bausch Health Companies Inc, sent a letter to the drugmaker's chief executive on Friday, saying the spinoff of the Canadian company's eye care unit should be completed by the end of 2021.

Bausch Health shareholder says eye care spinoff should be completed in 2021

Glenview Capital Management, a shareholder in Bausch Health Companies Inc, said on Friday the Canadian drugmaker should spin off its eye care unit, Bausch Global Eyecare, in an "optimal fashion" in 2021.

Bausch Health to spin off eye care business, shares soar

Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.

CANADA STOCKS-TSX scales 5-month high on Bausch Health, oil surge

Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch Health and higher oil prices outweighed disappointment over earnings, including Bombardier's surprise quarterly loss.

Bausch Health to spin-off eye care business

Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin-off its eye care unit Bausch + Lomb into a separate publicly listed company.

Bausch Health, three former executives agree to penalties to resolve U.S. SEC charges

Bausch Health Companies Inc <BHC.TO> has agreed to pay $45 million, and three of former top executives also agreed to penalties, to settle charges of improper revenue recognition and misleading disclosures in U.S. regulatory filings, the U.S. Securities and Exchange Commission...

Bausch Health agrees to pay $45 mln to settle U.S. charges of misleading disclosures

Canada-based Bausch Health Companies Inc has agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in Securities and Exchange Commission filings and earnings presentations, the SEC said on Friday.

BRIEF-Health Canada Issues Notice Of Compliance For Bausch Health's DUOBRII

* HEALTH CANADA ISSUES NOTICE OF COMPLIANCE FOR BAUSCH HEALTH'S DUOBRII™

Exclusive: Chanel, Revlon, L'Oreal pivoting away from talc in some products

Chanel, Revlon and L'Oreal, three of the biggest brands in cosmetics, are quietly moving away from using talc in some products as U.S. cancer lawsuits and consumer concerns mount.

BRIEF-FDA Provides 510(K) Clearance For Bausch + Lomb Infuse™ Contact Lenses

* FDA PROVIDES 510(K) CLEARANCE FOR BAUSCH + LOMB INFUSE™ DAILY DISPOSABLE SILICONE HYDROGEL (SIHY DAILY) CONTACT LENSES

CORRECTED: Special master says he will approve $1.21 bln Bausch securities settlement

A federal special master said Wednesday that he would grant final approval to a $1.21 billion settlement by Bausch Health Cos Inc of a shareholder class action alleging the company misled investors about its business operations and financial performance when it was called...

Judge tosses whistleblower lawsuit accusing Bausch Health of patent abuse

A judge on Monday tossed a whistleblower lawsuit alleging Bausch Health Companies Inc fraudulently obtained a patent on its ulcerative colitis drug Apriso, causing artificially high prices to be charged to Medicare and Medicaid.

BRIEF-Bausch Health Reports Launch Of Private Offering Of Senior Notes

* BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES AND CONDITIONAL REDEMPTION OF EXISTING SENIOR SECURED NOTES

BRIEF-Bausch Health And Alfasigma Announce Resolution Of Xifaxan Intellectual Property Litigation

* BAUSCH HEALTH AND ALFASIGMA ANNOUNCE RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION

BRIEF-FDA Approves Ortho Dermatologics' Labeling For Jublia (Efinaconazole) Topical Solution

* FDA APPROVES ORTHO DERMATOLOGICS' LABELING FOR JUBLIA® (EFINACONAZOLE) TOPICAL SOLUTION, 10%, IN PATIENTS AS YOUNG AS SIX YEARS OLD

BRIEF-Clearside Biomedical Revises NDA Resubmission Timeline And XIPERE Commercial Deal With Bausch Health

* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH

BRIEF-Bausch Health Initiates Virazole Clinical Study In Patients With COVID-19

* BAUSCH HEALTH INITIATES VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) CLINICAL STUDY IN PATIENTS WITH COVID-19

BRIEF-Glenview Capital Management LLC Reports 5.10% Passive Stake In Bausch Health Companies

* GLENVIEW CAPITAL MANAGEMENT LLC REPORTS 5.10% PASSIVE STAKE IN BAUSCH HEALTH COMPANIES INC AS OF APRIL 8 - SEC FILING Source text : (https://bit.ly/3b80eyg) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up